Are Exosome Injections FDA-Approved in the United States?
- Updated November 14, 2026
- Stop 2 of 4 on the FDA status and safety line
No. As of November 14, 2026, FDA’s directory of approved cellular and gene therapy products, a list of products licensed by its Office of Therapeutic Products marked “Content current as of 10/30/2026,” lists no exosome or extracellular vesicle product. That directory check is a strong signal, but for any specific product the label and FDA approval letter are the final word. FDA’s own public statements from December 2019 said there were no FDA-approved exosome products, and the current directory still lists none. Status can change, so the verification steps below show how to check a specific product on the day you are deciding.
What does the FDA regulate when exosomes are sold as injections?
Exosomes are tiny vesicles released by cells; the biology is explained in our article on what exosomes are and what they do. Once a product containing them is marketed to diagnose, treat or prevent a disease, FDA treats it as a drug and biological product. In its December 2019 public safety notification, FDA stated that exosomes used to treat diseases in humans are regulated as drugs and biological products and require premarket review and approval.
That premarket review is product-specific. It examines how a particular product is made, what is in it, and what controlled human studies show for a named use. An approval, if one is ever granted, belongs to that product and that use; general laboratory findings about vesicles do not substitute for it.
What do official FDA warnings say about unapproved exosome products?
| Date | FDA document | What it says |
|---|---|---|
| December 6, 2019 | Public safety notification on exosome products | No FDA-approved exosome products existed; FDA learned of multiple serious adverse events in Nebraska patients treated with unapproved products marketed as containing exosomes |
| December 9, 2019 | Public safety alert on unapproved stem cell and exosome products | Repeated that no exosome products were approved and warned that unsubstantiated claims could delay legitimate treatment |
| July 22, 2020 (content current as of April 9, 2024) | Consumer alert on regenerative medicine products | No exosome products are FDA-approved; exosome products intended to treat disease require approval |
The 2019 documents did not describe the route of administration or the specific types of adverse events reported in Nebraska. They are evidence of FDA’s concern and of the approval status at that time. They are not, on their own, proof of today’s status, which is why the directory check matters.
You can read the December 2019 safety alert and the 2020 consumer alert directly.
Does FDA registration, a facility listing or trial enrollment mean an exosome injection is approved?
No. Each of these is a real regulatory or administrative step, but none is a product approval.
| Claim you may see | What it actually establishes | What it does not establish |
|---|---|---|
| "FDA approved" | If true, a licensed product with a labeled use you can find on FDA's site | Approval for any use not on the label |
| "FDA registered" | A facility has registered and listed products with FDA | That FDA reviewed the product's safety or effectiveness |
| "We have an IND" | FDA allowed a product to be studied in a clinical investigation | That the product works or may be sold as treatment |
| "Listed on ClinicalTrials.gov" | A study was registered by its sponsor | Approval, safety, effectiveness or legitimacy of a clinic's off-study offer |
FDA’s patient information page on regenerative medicine makes the same point: a firm registering with FDA, or a study appearing on ClinicalTrials.gov, does not mean a product is legally marketed. The same page says that charging for these products or offering them outside a clinical trial likely means the offer is deceptive and illegal.
Can an exosome product be studied in an authorized clinical trial?
Yes. A sponsor can study an investigational exosome product under an IND. In that setting, FDA’s 2019 notice describes what a participant should expect: a consent form explaining the procedure, an Institutional Review Board overseeing participant protections, and the option to ask for the investigator’s brochure describing the product and what is known about its safety and effectiveness.
Participation in a properly overseen study is a different thing from buying an injection at a clinic. A trial is designed to find out whether the product works and what it harms; the answer is unknown at the start. An IND therefore tells you oversight exists. It does not tell you the product is effective, and it does not convert the product into an approved treatment.
FDA also notes that it does not oversee treatments performed in other countries.
How can patients verify a particular product or trial?
- Get the exact product name and sponsor. Ask the provider which company makes the product and what it is called. A description such as “stem cell exosomes” is not enough to verify anything.
- Search FDA’s approved products directory for that name. If it is not there, treat any approval claim as unconfirmed and ask the provider for the product’s FDA approval letter and prescribing information (the label); an approved product has both, and the label names the approved use.
- If the provider says the injection is part of a study, ask for the NCT number of the study record and the IND number with the FDA communication acknowledging it. FDA suggests confirming this with your own clinician.
- Open the NCT record yourself and check that the study, product, sponsor and location match what you are being offered. Our guide to finding and reading stem cell clinical trials walks through the record fields.
- Ask whether you will be charged, and for what. FDA’s patient page treats charging for these products outside a clinical trial as a sign the offer is likely deceptive and illegal. Separate the product’s price from fees for visits or routine care. FDA does allow limited cost recovery in some studies or expanded access cases, but only within FDA’s rules, and that exception does not apply automatically to a clinic’s offer; ask the provider to show FDA’s authorization.
- Record the date of your check, because approval status can change.
If you were harmed after an exosome injection, FDA’s MedWatch program accepts reports from patients and health professionals, online or by form.
Status block: what to recheck
This answer reflects FDA’s approved cellular and gene therapy products directory as read on November 14, 2026 (the page’s “Content current as of” date was October 30, 2026) and FDA’s 2019 and 2020 exosome statements. Anyone relying on it later should repeat the directory search and note the date.
Does an IND mean the FDA endorses an exosome treatment? No. An IND permits investigation under oversight; it is not an endorsement of effectiveness or a license to market.
Does a clinical-trial listing prove safety? No. Registration describes a planned or ongoing study. Safety is what the study is trying to measure.
Every stop on the FDA status and safety line
- Which Stem Cell Therapies Are FDA-Approved in the United States?
- Are Exosome Injections FDA-Approved in the United States?
- What Are the Risks of Unapproved Stem Cell Injections?
- How to Check Whether a Stem Cell Clinic’s Claims Are Supported by Evidence
Leave a note on this stop